CN1033509C - 一种新的制备喜树碱衍生物的方法 - Google Patents

一种新的制备喜树碱衍生物的方法 Download PDF

Info

Publication number
CN1033509C
CN1033509C CN91110656A CN91110656A CN1033509C CN 1033509 C CN1033509 C CN 1033509C CN 91110656 A CN91110656 A CN 91110656A CN 91110656 A CN91110656 A CN 91110656A CN 1033509 C CN1033509 C CN 1033509C
Authority
CN
China
Prior art keywords
compound
hydrogen
camptothecine
camptothecin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN91110656A
Other languages
English (en)
Chinese (zh)
Other versions
CN1062731A (zh
Inventor
J·M·福图纳克
J·L·伍德
A·R·马斯特罗科拉
M·梅林杰
P·L·伯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1062731A publication Critical patent/CN1062731A/zh
Application granted granted Critical
Publication of CN1033509C publication Critical patent/CN1033509C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
  • Steroid Compounds (AREA)
CN91110656A 1990-09-28 1991-09-28 一种新的制备喜树碱衍生物的方法 Expired - Lifetime CN1033509C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58964390A 1990-09-28 1990-09-28
US589,643 1990-09-28

Publications (2)

Publication Number Publication Date
CN1062731A CN1062731A (zh) 1992-07-15
CN1033509C true CN1033509C (zh) 1996-12-11

Family

ID=24358879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN91110656A Expired - Lifetime CN1033509C (zh) 1990-09-28 1991-09-28 一种新的制备喜树碱衍生物的方法

Country Status (24)

Country Link
US (1) US5734056A (OSRAM)
EP (1) EP0547165B1 (OSRAM)
JP (1) JP2848958B2 (OSRAM)
CN (1) CN1033509C (OSRAM)
AT (1) ATE186461T1 (OSRAM)
AU (1) AU664830B2 (OSRAM)
CA (1) CA2090967C (OSRAM)
CZ (1) CZ51593A3 (OSRAM)
DE (1) DE69131775T2 (OSRAM)
DK (1) DK0547165T3 (OSRAM)
ES (1) ES2137932T3 (OSRAM)
FI (1) FI931384A0 (OSRAM)
GR (1) GR3031823T3 (OSRAM)
HU (1) HUT70024A (OSRAM)
IE (1) IE913402A1 (OSRAM)
IL (1) IL99571A (OSRAM)
NO (1) NO931153D0 (OSRAM)
NZ (1) NZ239947A (OSRAM)
PT (1) PT99109B (OSRAM)
SI (1) SI9111599A (OSRAM)
SK (1) SK283693B6 (OSRAM)
WO (1) WO1992005785A1 (OSRAM)
YU (1) YU159991A (OSRAM)
ZA (1) ZA917748B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5527913A (en) * 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
JPH08333370A (ja) * 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6407118B1 (en) 1996-01-30 2002-06-18 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
GB9601779D0 (en) * 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2004055020A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
AU2003223109A1 (en) * 2003-03-31 2004-10-25 Council Of Scientific And Industrial Research Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
AU2004238358B2 (en) 2003-05-12 2010-05-13 Scinopharm Taiwan, Ltd. Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ298934B6 (cs) * 2003-08-26 2008-03-12 Pliva- Lachema A.S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
EP1791846A1 (en) * 2004-08-09 2007-06-06 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
AU2005301500B2 (en) * 2004-11-05 2011-02-03 Samyang Biopharmaceuticals Corporation Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents
US20060135546A1 (en) * 2004-12-16 2006-06-22 Jagadevappa Basavaraja Methods for the purification of 20(S)- camptothecin
EP1906948A4 (en) * 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
KR20080068052A (ko) * 2005-10-10 2008-07-22 씨아이피엘에이 엘티디. 신규의 결정형
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080039485A1 (en) * 2006-08-08 2008-02-14 Targetgen Biotechnology Co., Ltd. Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CA2662517A1 (en) * 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
EP2061479A4 (en) * 2006-09-05 2010-08-04 Bipar Sciences Inc FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
US7977483B2 (en) 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
JPWO2009054332A1 (ja) 2007-10-23 2011-03-03 萬有製薬株式会社 ピリドン置換ジヒドロピラゾロピリミジノン誘導体
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
JP2011503071A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
CN101450949B (zh) * 2007-12-07 2011-10-05 上海龙翔生物医药开发有限公司 一种10-羟基喜树碱的化学半合成工艺
MX2010006154A (es) * 2007-12-07 2010-09-24 Bipar Sciences Inc Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
JP5376532B2 (ja) 2008-05-29 2013-12-25 日本マイクロバイオファーマ株式会社 カンプトテシン誘導体の製造方法
JP2012518598A (ja) 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
WO2010101734A1 (en) 2009-03-06 2010-09-10 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2012082337A2 (en) 2010-12-17 2012-06-21 Glaxo Wellcome Manufacturing Pte Ltd Combination
US20130303560A1 (en) 2011-02-01 2013-11-14 Sunnybrook Research Institute Combination
CN103145720B (zh) * 2013-02-20 2015-09-30 上海北卡医药技术有限公司 一种10-羟基喜树碱的一水合物的制备方法
EP2881396A1 (en) * 2013-12-03 2015-06-10 Synbias Pharma AG Method for the synthesis of irinotecan
CN109475590A (zh) * 2016-03-08 2019-03-15 成氏实验室有限公司 用以提升人体酸碱度从酸性变为碱性的中药配方制剂
CN115551552A (zh) 2020-02-25 2022-12-30 祐方有限公司 喜树碱衍生物及其缀合物
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
JP2025516629A (ja) 2022-05-11 2025-05-30 セルジーン コーポレーション Ｔ細胞療法に関連する方法および使用、ならびにその生成

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5842192B2 (ja) * 1974-05-18 1983-09-17 フセソユ−ズヌイ ナウチノ イスレドワ−チエレスキ− ヒミコ フアルマツエフチチエスキ− インスチツ−ト イメ−ニ エス オルジヨニキ−ゼ ５− オキシ −６− アミノメチルベンゾフランノ ユウドウタイノ セイホウ
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS595188A (ja) * 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5946284A (ja) * 1982-09-10 1984-03-15 Yakult Honsha Co Ltd １１−ニトロカンプトテシン誘導体およびその製造法
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
US5352789A (en) * 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds

Also Published As

Publication number Publication date
PT99109B (pt) 1999-02-26
HUT70024A (en) 1995-09-28
DK0547165T3 (da) 2000-03-27
PT99109A (pt) 1992-08-31
ATE186461T1 (de) 1999-11-15
EP0547165A1 (en) 1993-06-23
EP0547165B1 (en) 1999-11-10
YU159991A (sh) 1994-06-10
HK1012283A1 (en) 1999-07-30
IL99571A (en) 2000-08-31
DE69131775D1 (de) 1999-12-16
JP2848958B2 (ja) 1999-01-20
SK283693B6 (sk) 2003-12-02
FI931384L (fi) 1993-03-26
EP0547165A4 (OSRAM) 1994-03-30
SK25993A3 (en) 1993-07-07
FI931384A7 (fi) 1993-03-26
HU9300878D0 (en) 1993-06-28
DE69131775T2 (de) 2000-04-20
IE913402A1 (en) 1992-04-08
CA2090967C (en) 2007-02-06
CZ51593A3 (en) 1994-01-19
GR3031823T3 (en) 2000-02-29
JPH06501476A (ja) 1994-02-17
AU664830B2 (en) 1995-12-07
NO931153L (no) 1993-03-26
CN1062731A (zh) 1992-07-15
CA2090967A1 (en) 1992-03-29
NO931153D0 (no) 1993-03-26
ZA917748B (en) 1992-09-30
IL99571A0 (en) 1992-08-18
FI931384A0 (fi) 1993-03-26
WO1992005785A1 (en) 1992-04-16
AU8739991A (en) 1992-04-28
ES2137932T3 (es) 2000-01-01
NZ239947A (en) 1994-07-26
US5734056A (en) 1998-03-31
SI9111599A (sl) 1998-02-28

Similar Documents

Publication Publication Date Title
CN1033509C (zh) 一种新的制备喜树碱衍生物的方法
CN1029967C (zh) 新的黄嘌呤衍生物的制备方法
CN1037439C (zh) 制备具有神经保护作用的吲哚酮及有关衍生物的方法
CA2287046C (fr) Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1022566C (zh) 制备新的取代的1-哌啶亚烷基-吡啶并嘧啶酮或噻唑并嘧啶酮的方法
CN1045089C (zh) 2－(2－氨基－1,6－二氢－6－氧代－嘌呤－9－基)甲氧基－1,3－丙二醇衍生物
CN1703404A (zh) 制备10,11－二氢－10－羟基－5H－二苯并(b,f)氮杂䓬－5－甲酰胺的两种对映异构体的对映选择性方法及其新晶形
CN87101691A (zh) 碳环嘌呤核苷，它们的制备及应用
CN1560055A (zh) 四氢吡啶醚化合物
CN1108653A (zh) 2-脱苯甲酰基-2-酰基紫杉醇衍生物及其制备方法
CN1035295A (zh) 腺苷衍生物
CN1109471A (zh) 咪唑-4-基哌啶衍生物及其制备方法和在治疗中的应用
CN86106194A (zh) 抗精神病的γ-咔啉
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
CN1028528C (zh) 旋光活性4-羟基-8-(3-低烷氧基-4-苯基亚磺酰基苯基)吡唑并[1，5-α]-1，3，5-三嗪或其盐的制法
CN1276927C (zh) 维生素d衍生物结晶及其制备方法
CN1105360A (zh) 1-[2h-1-苯并吡喃-2-酮-8-基]-哌嗪衍生物
CN1073936A (zh) α-取代的苯甲胺衍生物
CN1048014C (zh) 取代的吡咯类化合物及其制法、药物组合物和用途
CN1009826B (zh) 制备喹啉基化合物的方法
CN1135483A (zh) 喹喔啉及其制备方法与应用
CN1013111B (zh) 制备苯并氮杂环癸五烯衍生物的方法
CN1056102A (zh) 新的哒嗪及其制备方法
CN1117754C (zh) 吲哚并吗啡喃衍生物及其组合物
CN1656100A (zh) 带有修饰的内酯环的喜树碱

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20110928

Granted publication date: 19961211